

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mark Chao on November 10, 2005.

Claim 1: (currently amended) A monoclonal antibody that specifically binds to a peptide having an amino acid sequence of residues 12 to [20] 24 of SEQ ID NO: 2.

Claim 12: (currently amended) The method of claim 6, in which the monoclonal antibody is P2L-1Ta [as secreted by hybridoma NIBH 6300].

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao-Thuy L. Nguyen whose telephone number is (571) 272-0824. The examiner can normally be reached on Tuesday and Wednesday from 8:00 a.m. -4:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (571) 272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/700,643
Filed: 2/2/2001
1st Inventor: Matsumoto, Hirokazu
For: Antibody and Use Thereof
Atty. Dkt. No. 2523 USOP

Art Unit: 1641
Examiner: NGUYEN, B
Allowed: 9/8/04
Batch:
Paper No.:

RECEIVED
CENTRAL FAX CENTER

DEC 03 2004

REQUEST FOR AMENDMENT under 37 CFR 1.312, No Issue Fee Paid**MAIL STOP ISSUE FEE****VIA FACSIMILE TO 1-703-872-9306**

Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450
Sir:

Applicants respectfully request the following amendment to correct an obvious typographical/grammatical error in the claims of this allowed case.

No issue fee has been paid in this case as of the filing of this request.

AMENDMENT

Please rewrite the renumbered claims to read as follows:

~~1. (PREVIOUSLY PRESENTED) A monoclonal antibody that specifically binds to a peptide having an amino acid sequence of residues 12 to 20 of SEQ ID NO:2.~~

2. (PREVIOUSLY PRESENTED) The monoclonal antibody as claimed in Claim 1 which is a mouse IgG.

3. (CURRENTLY AMENDED) A method of detecting 19P2 ligand in a test fluid which comprises using the monoclonal antibody of Claim 1 in an assay, said assay comprising:

contacting the test fluid sample with said monoclonal antibody,
and
detecting any complexes ~~form~~ formed from the binding of said 19P2
ligand with said monoclonal antibody, and
relating the ~~present~~ presence or amount of said complexes to the
~~present~~ presence or amount of 19P2 ligand in said sample.

4. (PREVIOUSLY PRESENTED) An isolated hybridoma cell
producing the monoclonal antibody as claimed in Claim 1.

5. (PREVIOUSLY PRESENTED) The monoclonal antibody of claim
1, which specifically binds with a peptide having the amino acid
sequence of SEQ ID NO: 11.

6. (CURRENTLY AMENDED) A method for detecting 19P2 ligand in
a sample, comprising:

contacting said sample with a monoclonal antibody of claim
5, and

detecting any complexes ~~form~~ formed from the binding of said
19P2 ligand to said monoclonal antibody, and

relating the ~~present~~ presence or amount of said complexes to
the ~~present~~ presence or amount of 19P2 ligand in said sample.

7. (PREVIOUSLY PRESENTED) The method of claim 6 further
comprising: assaying said sample wherein said 19P2 ligand is
attached to a carrier.

8. (PREVIOUSLY PRESENTED) The method of claim 6 wherein
said monoclonal antibody is attached to a carrier.

9. (PREVIOUSLY PRESENTED) The method of claim 6 wherein said monoclonal antibody is attached to a detectable signal or label.

10. (PREVIOUSLY PRESENTED) The method of claim 6 which is a sandwich assay.

11. (PREVIOUSLY PRESENTED) The method of claim 6 which is a competitive inhibition assay.

12. (PREVIOUSLY PRESENTED) The method of claim 6 in which the monoclonal antibody is P2L-1Ta as secreted by hybridoma NIBH 6300.

13. (CURRENTLY AMENDED) A method for detecting 19P2 ligand in a sample, comprising:

contacting said sample with the monoclonal antibody of claim 5 and a second antibody comprising an antibody which specifically binds to a peptide having the amino acid sequence of SEQ ID NO: 7, and

detecting any complexes ~~form~~ formed from the binding of the monoclonal antibody of claim 11, said 19P2 ligand and said second antibody, and

relating the ~~present~~ presence or amount of said complexes to the ~~present~~ presence or amount of 19P2 ligand in said sample.

14. (PREVIOUSLY PRESENTED) The monoclonal antibody of Claim 1, which specifically binds with a peptide having the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:12.

15. (CURRENTLY AMENDED) The monoclonal antibody of claim 1, which specifically binds with a peptide having the amino acid sequence of amino acid residues 12 to 24 of ~~or~~ SEQ ID NO:1, amino acid residues 12 to 24 of SEQ ID NO:2, or amino acid residues 12 to 24 of SEQ ID NO:3.

16. (PREVIOUSLY PRESENTED) The monoclonal antibody of claim 1, which specifically binds with a 19P2 ligand peptide, but which does not bind with a peptide having the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6.

17. (PREVIOUSLY PRESENTED) The monoclonal antibody of Claim 1 which is P2L-1Ta as secreted by hybridoma NIBH 6300.

18. (PREVIOUSLY PRESENTED) An isolated hybridoma cell line, having accession number NIBH 6300, said cell line producing the antibody P2L-1Ta.